AI Article Synopsis
- - The NCCN Guidelines focus on identifying genetic variants that increase the risk of breast, ovarian, pancreatic, and prostate cancers, specifically targeting genes like BRCA1, BRCA2, and TP53.
- - The updated guidelines now include a section addressing the needs of transgender, nonbinary, and gender diverse individuals regarding cancer risk reduction strategies.
- - New criteria for testing and managing TP53 pathogenic variants and related risks of Li-Fraumeni syndrome have also been incorporated into the recommendations.
Article Abstract
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk of breast, ovarian, pancreatic, and prostate cancer, including BRCA1, BRCA2, CDH1, PALB2, PTEN, and TP53, and recommended approaches to genetic counseling/testing and care strategies in individuals with these P/LP variants. These NCCN Guidelines Insights summarize important updates regarding: (1) a new section for transgender, nonbinary and gender diverse people who have a hereditary predisposition to cancer focused on risk reduction strategies for ovarian cancer, uterine cancer, prostate cancer, and breast cancer; and (2) testing criteria and management associated with TP53 P/LP variants and Li-Fraumeni syndrome.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.6004/jnccn.2023.0051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!